A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

被引：0
|
作者：
Sekeres, MA [1 ]
Fu, AZ [1 ]
Maciejewski, JP [1 ]
Golshayan, AR [1 ]
Kalaycio, M [1 ]
Kattan, MW [1 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2533
引用
收藏
页码：711A / 711A
页数：1
相关论文
共 50 条
  • [21] High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes
    Latagliata, R.
    Oliva, E.
    Volpicelli, P.
    Napoleone, L.
    Carmosino, I.
    Breccia, M.
    Stefanizzi, C.
    Vincelli, I.
    Alati, C.
    Vozella, F.
    Nobile, F.
    Alimena, G.
    LEUKEMIA RESEARCH, 2009, 33 : S121 - S121
  • [22] Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes
    Gianelli, Umberto
    Fracchiolla, Nicola Stefano
    Cortelezzi, Agostino
    Pellegrini, Caterina
    Savi, Federica
    Moro, Alessia
    Grimoldi, Maria Grazia
    Deliliers, Giorgio Lambertenghi
    Coggi, Guido
    Bosari, Silvano
    ANNALS OF HEMATOLOGY, 2007, 86 (03) : 185 - 189
  • [23] Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
    Viniou, N
    Terpos, E
    Galanopoulos, A
    Kritikou-Griva, E
    Akel, S
    Michalis, E
    Apostolidou, E
    Georgiadou, D
    Kouraklis, A
    Parharidou, A
    Kokkini, G
    Symeonidis, A
    Anagnostopoulos, NI
    Christakis, JI
    Tasiopoulou, A
    Loukopoulos, D
    Yataganas, X
    ANNALS OF HEMATOLOGY, 2002, 81 (04) : 182 - 186
  • [24] Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
    N. Viniou
    E. Terpos
    A. Galanopoulos
    E. Kritikou-Griva
    S. Akel
    E. Michalis
    E. Apostolidou
    D. Georgiadou
    A. Kouraklis
    A. Parharidou
    G. Kokkini
    A. Symeonidis
    N. Anagnostopoulos
    J. Christakis
    A. Tasiopoulou
    D. Loukopoulos
    X. Yataganas
    Annals of Hematology, 2002, 81 : 182 - 186
  • [25] Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes
    Umberto Gianelli
    Nicola Stefano Fracchiolla
    Agostino Cortelezzi
    Caterina Pellegrini
    Federica Savi
    Alessia Moro
    Maria Grazia Grimoldi
    Giorgio Lambertenghi Deliliers
    Guido Coggi
    Silvano Bosari
    Annals of Hematology, 2007, 86 : 185 - 189
  • [26] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
    Ghaderi, Afshin
    Nodehi, Sayyed Reza Safaee
    Bakhtiari, Tahereh
    Aslani, Mona
    Aghazadeh, Zahra
    Matsuo, Hidenori
    Rehm, Bernd H. A.
    Cuzzocrea, Salvatore
    Mirshafiey, Abbas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07) : 879 - 888
  • [27] Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)
    Fenaux, P
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S11 - S15
  • [28] A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    Cutler, CS
    Lee, SJ
    Greenberg, P
    Deeg, HJ
    Pérez, WS
    Anasetti, C
    Bolwell, BJ
    Cairo, MS
    Gale, RP
    Klein, JP
    Lazarus, HM
    Liesveld, JL
    McCarthy, PL
    Milone, GA
    Rizzo, JD
    Schultz, KR
    Trigg, ME
    Keating, A
    Weisdorf, DJ
    Antin, JH
    Horowitz, MM
    BLOOD, 2004, 104 (02) : 579 - 585
  • [29] Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
    Volpe, Virginia O.
    Komrokji, Rami S.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [30] Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
    Ma, Xiaomei
    Wang, Rong
    Galili, Naomi
    Mayne, Susan T.
    Wang, Sa A.
    Yu, Herbert
    Raza, Azra
    CANCER CAUSES & CONTROL, 2011, 22 (04) : 623 - 629
12345